Treatment protocols
Treatment study protocols describe exactly how the physicians and staff will provide treatment to the patients, from pre-treatment to transplant and follow-up. These protocols provide information on the exact regimen of drugs to be given as conditioning therapy prior to transplantation, and on the recommendations for supportive care prior to and after transplantation. Some of the treatment clinical trials currently available include:
- This investigator-driven protocol outlines the full intensity treatment given for patients with leukemia, MDS, or lymphoma. It is standard treatment care for patients who are not otherwise eligible for experimental therapies, as well as those who prefer the current standard of care.
- This investigator-driven protocol is a reduced intensity conditioning protocol for related and unrelated hematopoietic stem cell transplantation. This approach can minimize the acute and chronic toxicities of transplantation.
- This investigator-driven study provides a reduced intensity transplant to patients with Severe Combined Immunodeficiency. A reduced intensity transplant is given to hopefully lead to the correction of the underlying immunological defects while causing fewer complications than a full intensity transplant.
- This investigator-driven study looks to provide reduced intensity conditioning prior to hematopoietic stem cell transplant to reduce short and long term toxicities that can occur after stem cell transplantation. Its goal is to reduce morbidity and mortality by reducing the intensity of pre-transplant chemotherapy.
- This multi-site study is a full intensity protocol. Unrelated, closely matched donors are used as the stem cell source for patients with severe sickle cell disease.
- This investigator-driven protocol studies the use of extracorporeal photopheresis (ECP) in combination with a reduced intensity conditioning protocol. This approach may minimize some acute and chronic toxicities of transplantation.
- This industry-sponsored protocol provides an alternative to a typical stem cell transplant for patients with certain types of leukemia and lymphoma who are unable to find a matched donor. This full-intensity transplant involves transplantation of a graft of expanded stem/progenitor cells from a single cord blood unit, as well as unmanipulated cells from the same cord blood unit.
- This multi-site study looks at the use of autologous stem cell rescue for patients with autoimmune disease. It provides transplant for patients with severe disease who have failed several different lines of alternate treatment.
- This consortium study involves recurrent/refractory brain tumor patients from a number of clinical sites. This protocol involves treatment both before and after an autologous stem cell transplant.
- Tandem autologous stem cell rescues are given to children with recurrent solid tumors. This investigator-driven protocol incorporates the use of double sequential high dose therapy regimens to treat patients who achieve a second complete remission or a partial response after a solid tumor. Patients determined to have chemosensitive disease are eligible.
- This industry-sponsored study looks at the safety and appropriate dosing of Palifermin for pediatric subjects with hematologic malignancies undergoing allogeneic transplantation. Future studies focusing on efficacy of Palifermin in reducing mucositis will be based on the dose level of Palifermin established in this study.
All protocols are approved by the Children's Memorial Hospital Institutional Review Board.